US Patent

US12364685 — Isoxazoline parasiticide formulations

Formulation · Assigned to Tarsus Pharmaceuticals Inc · Expires 2038-12-14 · 13y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects isoxazoline parasiticide formulations for treating or preventing ophthalmic and dermatologic conditions, such as blepharitis or rosacea.

USPTO Abstract

Disclosed herein are compositions which can be used in methods for treating or preventing ophthalmic and dermatologic conditions in a human subject, including ocular surface conditions such as blepharitis or rosacea. The compositions can be topically administered directly to an eye, eyelid, or eyelashes of the patient for targeted local activity.

Drugs covered by this patent

Patent Metadata

Patent number
US12364685
Jurisdiction
US
Classification
Formulation
Expires
2038-12-14
Drug substance claim
No
Drug product claim
Yes
Assignee
Tarsus Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.